Wim H A Dokter
Overview
Explore the profile of Wim H A Dokter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Helden M, Zwarthoff S, Arends R, Reinieren-Beeren I, Parade M, Driessen-Engels L, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37068796
Background: Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies...
2.
Groothuis P, Jacobs D, Hermens I, Damming D, Berentsen K, Mattaar-Hepp E, et al.
Mol Cancer Ther
. 2023 Apr;
22(6):765-777.
PMID: 37042205
MET, the cell-surface receptor for the hepatocyte growth factor/scatter factor, which is widely overexpressed in various solid cancer types, is an attractive target for the development of antibody-based therapeutics. BYON3521...
3.
Duro-Sanchez S, Nadal-Serrano M, Lalinde-Gutierrez M, Arenas E, Bernado Morales C, Morancho B, et al.
Cancer Res
. 2022 Oct;
82(24):4670-4679.
PMID: 36222720
Significance: Combining ADCs against HER2-positive breast cancers with therapies that induce cellular senescence may improve their therapeutic efficacy by facilitating a bystander effect against antigen-negative tumor cells.
4.
Coumans R, Ariaans G, Spijker H, Renart Verkerk P, Beusker P, Kokke B, et al.
Bioconjug Chem
. 2020 Jul;
31(9):2136-2146.
PMID: 32697078
Engineering cysteines at specific sites in antibodies to create well-defined ADCs for the treatment of cancer is a promising approach to increase the therapeutic index and helps to streamline the...
5.
Nadal-Serrano M, Morancho B, Escriva-de-Romani S, Bernado Morales C, Luque A, Escorihuela M, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32183023
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic...
6.
Ubink R, Dirksen E, Rouwette M, Bos E, Janssen I, Egging D, et al.
Mol Cancer Ther
. 2018 Aug;
17(11):2389-2398.
PMID: 30093567
Carboxylesterase 1c (CES1c) is responsible for linker-drug instability and poor pharmacokinetics (PK) of several antibody-drug conjugates (ADC) in mice, but not in monkeys or humans. Preclinical development of these ADCs...
7.
Black J, Menderes G, Bellone S, Schwab C, Bonazzoli E, Ferrari F, et al.
Mol Cancer Ther
. 2016 Jun;
15(8):1900-9.
PMID: 27256376
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu oncogene at strong (i.e., 3+) levels by IHC while an...
8.
Irwin N, Patterson S, de Kort M, Moffett R, Wisse J, Dokter W, et al.
ChemMedChem
. 2015 Jun;
10(8):1424-34.
PMID: 26059252
The present study details the development of a family of novel D-Ala(8) glucagon-like peptide-1 (GLP-1) peptide conjugates by site specific conjugation to an antithrombin III (ATIII) binding carrier pentasaccharide through...
9.
Elgersma R, Coumans R, Huijbregts T, Menge W, Joosten J, Spijker H, et al.
Mol Pharm
. 2015 Jan;
12(6):1813-35.
PMID: 25635711
Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug classes: auristatins and maytansinoids. Both are tubulin binders and block the...
10.
van der Lee M, Groothuis P, Ubink R, van der Vleuten M, van Achterberg T, Loosveld E, et al.
Mol Cancer Ther
. 2015 Jan;
14(3):692-703.
PMID: 25589493
SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload. To evaluate the therapeutic potential of this new ADC, mechanistic in vitro studies and...